Please assess the completion status of the following clinical trial:

Trial Title: Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with CML-CP treated for at least two years by Imatinib Mesylate 400 mg / d,~2. Patients in complete cytogenetic response for at least 1 year~3. Patients with residual disease detectable by quantitative RT-PCR (RQ-PCR)~4. ECOG ≤ 2,~5. Age ≥ 18 years~6. Signed informed consent,~7. Membership of a social security system~Exclusion Criteria:~1. Patients with CML-CP Philadelphia chromosome negative diagnosis.~2. Patients previously treated with Imatinib Mesylate at doses above 400 mg / day~3. Patient with non-hematologic toxicity of grade III or IV in Imatinib Mesylate 400mg / d~4. Patient with a medical condition endocrine, psychiatric, neurological, renal, hepatic or cardiac progressive uncontrolled by medical treatment~5. Pregnant or breastfeeding women, women of childbearing potential not using a contraceptive method effective~6. Known HIV positive~7. Patients previously treated with another tyrosine kinase inhibitor~8. Patient participating in another interventional clinical trial~9. History of non-compliance to Imatinib Mesylate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib 600 (Randomized trial) (Type: EXPERIMENTAL): Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po
- Imatinib 400 (Randomized trial) (Type: ACTIVE_COMPARATOR): Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po
- Imatinib400 (Cohort) (Type: OTHER): Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po

Based on this trial design, predict the completion outcome and termination type (if applicable).